In drug development, every delay has a price—lost time, lost opportunity, and lost market share. Escalating costs, complex modalities, strict regulations, and supply chain challenges are making speed and precision more critical than ever. Yet many programs remain slowed by fragmented outsourcing models that create inefficiencies, communication gaps, and costly handoffs.
Important new research from the Tufts Center for the Study of Drug Development points to a more effective path. Using a modeling approach that quantifies both the financial returns and risk-adjusted value of development decisions, the researchers found that integrating CDMO, CRO, and clinical supply capabilities with one a single partner can shorten timelines, reduce costs, and strengthen control.
This webinar will cover key findings from the study along with case-driven examples of how biotech and biopharma companies are applying these strategies to reach milestones faster and with greater strategic control.
Dr. Joseph DiMasi is an internationally recognized expert on the economics of the pharmaceutical industry. He serves on the editorial board of Therapeutic Innovation and Regulatory Science and has previously served on the editorial boards of the Drug Information Journal, the Journal of Research in Pharmaceutical Economics, and the Journal of Pharmaceutical Finance, Economics & Policy. He has published in a wide variety of economic, medical, and scientific journals and has presented his research at numerous professional and industry conferences. Dr. DiMasi testified before the U.S. Congress in hearings leading up to the FDA Modernization Act of 1997 and reauthorization of the Prescription Drug User Fee Act. He received the Donald E. Francke Award from the Drug Information Association for the best article in the Drug Information Journal published in 2000. Dr. DiMasi received his doctorate in economics from Boston College in 1984.
Dr. DiMasi’s research interests include the R&D cost of new drug development, clinical success and phase attrition rates, development and regulatory approval times, R&D efficiency, the role that pharmacoeconomic evaluations have played in the R&D process, pricing and profitability in the pharmaceutical industry, innovation incentives for pharmaceutical R&D, and changes in the structure and performance of the pharmaceutical and biotechnology industries.
Doug Ahrens is Program Transformation Director at Thermo Fisher Scientific, where he champions global integrated program strategy spanning Drug Substance, Drug Product, Clinical Supply, and Clinical Development services. With more than 30 years of experience in the clinical research and biopharmaceutical industries, Doug has held senior leadership roles in program management, strategic account governance, and integrated delivery solutions. Since joining Thermo Fisher in 2018, he has driven scalable governance models, global harmonization initiatives, and customer-focused solutions from pre-IND through BLA/NDA registration. Doug has authored multiple scientific publications and is a co-inventor on patents in the field of RNA aptamer-based therapeutics. He earned a Master of Arts in Biochemistry & Cellular Biology from the University of Kansas and a Bachelor of Science in Biology from the University of Maryland